Infant Anaphylaxis

Price: FREE for members and non-members

The incidence of anaphylaxis has increased globally among children. Infants present a special challenge regarding their presentation and treatment. Recognizing the early signs and symptoms is crucial to effective diagnosis and treatment. Finally, understanding nuances of treatment in this unique population is important for clinicians caring for children with allergies. Join our anaphylaxis experts Vivian Hernandez-Trujillo, MD, FACAAI and Jay Lieberman, MD, FACAAI for this FREE CME webinar.

This webinar is supported by an unrestricted educational grant from Kaléo.


The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learning Objectives

After completing this webinar, participants should be able to:

  1. Be familiar with causes of infantile anaphylaxis
  2. Recognize infant anaphylaxis and know the difference compared to children and adults
  3. Provide correct treatment and prevention procedures for infants with a history of anaphylaxis
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

All identified conflicts of interest have been resolved.

Vivian Hernandez-Trujillo, MD, FACAAI: Clinical Associate Professor, Florida International University Herbert Wertheim College of Medicine; Director, Division of Allergy and Immunology, Nicklaus Children’s Hospital, Miami; Allergy and Immunology Care Center - South Florida, LLC. Advisory Board Member: Consulting Fees; Bayer, CSL, Kaleo, Shire. Speaker: Honorarium; Bayer, CLS, Kaleo. Consultant; Consultant Fee; Kaleo.

Jay Lieberman, MD, FACAAI: Associate Professor, University of Tennessee Health Science Center and LeBonheur Children’s Hospital, Memphis; Associate Editor, Annals of Allergy, Asthma & Immunology. Advisory Board Member: Consulting Fees; Aimmune Therapeutics, ALK Abello, DBV Technologies. Principal Investigator and Author: Contracted Research; Aimmune Therapeutics, DBV Technologies. Consultant: Consulting fees; Kaleo.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
Course expires: 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.